Hormone therapy options after previous CDK4/6 treatment for advanced breast cancer
Part of Cancer clinical trials.
This study compares two hormone therapy approaches for advanced breast cancer that has returned after completing at least one year of a CDK4/6 inhibitor (like abemaciclib or ribociclib) taken with hormone therapy. It aims to see if a different hormone therapy combination works better than the doctor's choice of treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- Your breast cancer is hormone receptor-positive (HR+) and HER2-negative, meaning it grows in response to hormones and does not have excess HER2 protein.
- Your cancer has spread or returned in the body and cannot be cured with local treatments.
- You previously took a CDK4/6 inhibitor (abemaciclib or ribociclib) for at least 1 year as part of your initial treatment, and your cancer returned at least 1 year after your last dose of that medication.
- You have not received any other treatment for advanced breast cancer yet.
- You are physically able to perform daily activities (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a type of targeted therapy (called CDK4/6 inhibitors) combined with hormone therapy works as the first treatment for advanced breast cancer that is hormone receptor-positive and HER2-negative. Researchers want to find patterns that could help predict which patients benefit most.
This study looks at patients whose breast cancer returns after starting a CDK4/6 inhibitor (like abemaciclib or ribociclib) along with hormone therapy. The goal is to understand why the cancer comes back and find better ways to treat it.
This trial tests giving a CDK4/6 inhibitor (a drug that slows cancer growth) along with hormone therapy before breast cancer surgery. It aims to shrink tumors in people who couldn't complete or benefit from standard chemotherapy, offering a potential alternative.
This study is looking at how well people stick to a treatment plan that combines hormone therapy with a pill called a CDK4/6 inhibitor after surgery for early-stage breast cancer. The goal is to learn more about adherence so doctors can help patients stay on track.
This study looks at how well CDK4/6 inhibitors combined with hormone therapy work in real-world settings for people with a certain type of advanced breast cancer (HR+/HER2-). It aims to understand the best treatment path and what happens next.
This study looks at how well a combination of two medicines (a CDK4/6 inhibitor and an aromatase inhibitor) works for people with a certain type of advanced breast cancer. It aims to gather real-world information to better understand treatment patterns and outcomes.
Hear when a new Breast Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.